Morningstar

China Resources Pharma: Placing Coverage Under Review

""
Securities In This Article
China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S
(03320)

We are placing coverage of narrow-moat-rated China Resources Pharmaceutical 03320 under review pending the transfer of coverage to a new analyst. We expect to revisit our coverage of this company over the next three months. Our most recent fair value estimate was HKD 6.40.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

Our Top Pick for Investing in US Renewable Energy

Utility-scale solar and battery storage installations are poised to set records in 2024.
Brett Castelli

Undervalued by 25% and Yielding 5%, This Stock Is a Buy

One important trend should propel long-term growth here.
Kevin Brown, CFA

Can AI Predict Future Stock Returns?

Artificial intelligence can outperform human analysts. But together, they prove hard to beat.
Larry Swedroe

About the Author

Yurou Zheng

Equity Analyst
More from Author

Yurou Zheng is an equity analyst, Asia, for Morningstar*. She covers stocks in the healthcare sector for the Asia team. Her coverages include biotech or biopharmaceuticals, medical device companies, and service providers.

Before joining the equity research team in 2022, Zheng was in the Morningstar Fund Data team for a regulation-driven project in the Australian market. Prior to Morningstar, she worked in a start-up venture capital fund covering the healthcare sector and worked at PwC Deals in Italy.

Zheng holds a bachelor’s degree in International Economics and Finance from Bocconi University. She also passed the examination for the Fund Practitioner Qualification by the Asset Management Association of China (AMAC) in 2021.

* Morningstar Investment Adviser Singapore Pte. Ltd. (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center